Cassava Sciences Inc. (SAVA)
NASDAQ (CM) 
SAVA STOCK ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CassavaSciences, Inc. - SAVA
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Cassava Sciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cassava Sciences, Inc. (SAVA)
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Cassava Sciences, Inc. (SAVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cassava Sciences, Inc. (SAVA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
Cassava Sciences, Inc. Being Investigated on Behalf of Cassava Sciences, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cassava Sciences, Inc. (SAVA) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
Cassava Sciences, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SAVA
NEW YORK, NY / ACCESSWIRE / November 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
